This can directly determine how the fusion executes its oncogenic function: for example, PAX3::FOXO1 (fusion-positive rhabdomyosarcoma) binds DNA at sites determined by the PAX3 DNA-binding domains, whereas FOXO1 provides transactivating capacity (9, 10). The gene discussed is FOXO1; the disease is rhabdomyosarcoma.